Categories AlphaGraphs, Analysis, Health Care

Amarin earnings preview: Expect higher revenues, but wider losses in Q1

Amarin Corporation (NASDAQ: AMRN) is scheduled to report first-quarter 2019 earnings results on Wednesday, May 1, before the opening bell. Analysts expect the biopharmaceutical firm to report a loss of $0.11 per share during the quarter, four cents wider than the loss it posted last year.

The bottom line will likely feel the pressure as the Dublin-based firm shells out more money on the promotion and marketing of its Vascepa capsules. The company will also incur charges related to its label expansion applications.

Vascepa lowers fat level in blood by reducing triglycerides in the body when taken along with a proper diet.

Amarin's Q4 2018 prescription growth trend for Vascepa

Revenue is expected to jump about 64% to $72.2 million, riding on the strong demand for its Vascepa capsules. Separately, as Amarin expands the sale of Vascepa across international markets, it is set to receive higher commercialization fees from its licensed partners.

Earlier today, the company announced that it has filed a New Drug Submission with Health Canada for Vascepa.

Amarin shares have gained 46% since the beginning of this year, outperforming the industry which has grown just over 2%. Three events had set the stage for the stock rally this year: Rumors that Novartis (NYSE: NVS) was interested in acquiring it; a better-than-expected revenue growth in Q4; and reports that the American Diabetes Association had given a positive note on its Vascepa capsule.

In Q4

In the last reported quarter, Amarin surpassed analysts’ expectations on revenues, while net loss came in higher-than-expected. Shares rose 3.9% in premarket hours on Wednesday.

READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS

Total revenues of $77.3 million were up 44% year-over-year, primarily reflecting Vascepa prescription growth. Net product revenue totaled $77.1 million, mainly due to increased Vascepa prescriptions in the US.

The stock has a 12-month price target of $38.67, suggesting a 100% upside from the last close.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top